This page focusses onstructural changes that occur when drugs undergo biotransformation and its importance in drug design and medicinal chemistry.Here, we also talk aboutdrug metabolism and the essential factors that underpin this central discipline in medicine.
Following entry to the body, drug molecules undergo metabolic transformations to derivatives known as metabolites. These metabolic transformations are sometimes referred to as biotransformations. The body generally identifies drugs as foreign substances andenzymes such as the Cytochrome P450 superfamily are heavily involved in the metabolism of foreign (xenobiotic) substances.The human body is armed with numerous metabolic enzymes that mediate the conversion of xenobiotic compounds to more excretable compounds.
Most small drug molecules are relatively lipophilic and in the body, they are modified or broken down such that they are readily more excretable. Often these break-down products (metabolites) are more hydrophilic than their parent drug.Metabolites may possess a different level of activity as the starting compound or none at all. Moreover, metabolites may possess different biological activity or may be toxic to the patient. In some cases,a parent drug may be inactive but is eventually converted to the active metabolite in the body. These drugs are referred to as prodrugs. Prodrugs were discussed in greater detail in a previous article (see link underFurther Reading).
Drug metabolism can be divided into the Phase I reactions (functionalisation) and the Phase II reactions (conjugation). Phase I biotransformations include oxidation, reduction, and hydrolysis reactions. Often these reactions involve the introduction of polar functional groups such as –OH to drug molecules to make them more hydrophilic. This can be done by directly introducing a functional group or by converting an existing functional group in a drug to more hydrophilic ones. The metabolites of Phase I reactions often undergo Phase II reactions where small, ionisable, and polar compounds are attached to the new functional groups. Phase I and Phase II reactions complement each other in the modification and excretion of xenobiotic compounds.
Oxidative processes, which involve the Cytochrome P450 (CYP450) superfamily of enzymes, are the most common. These enzymes are haemoproteins (i.e. they contain haem and iron) and involve molecular oxygen (O2). CYP450 enzymes belong to a class of enzymes known as monooxygenases. during metabolism. The reader is directed to the first article for a more detailed discussion of the CYP450 enzymes. The general formula of oxidative biotransformationsis shown below:
Activated carbons or readily accessible carbons are readily oxidised. For instance, unhindered methyl substituents are often oxidised to form alcohols, which can undergo further oxidation to the carboxylic acid.Other carbons such as carbon atoms in the alpha position to a heteroatom can also undergo oxidation.
Aromatic hydroxylation of arenes to arenols can also happen. In the case of benzene, the para position is often favoured. An example of a drug that undergoes aromatic hydroxylation is phenobarbital.
The CYP450 enzymes have rich chemistry and the diagram shown below is a small subset of reactions they can catalyse (see below).
Drug metabolism is often considered during drug design. For instance, a drug containing a benzene group may undergo Phase I reactions (e.g.hydroxylation of the ring, favouring the para position). This biotransformation can be deterred by replacing the hydrogen at the paraposition and using fluorine as a bioisostere. The role of fluorine as a bioisostere has been briefly introduced in a previous article.
On average, the bond dissociation energy of the C-F is around 425 kJ mol-1 andas a result, C-F bonds generally resist metabolism. Furthermore, due to the similar van der Waals radii of hydrogen and fluorine, replacement of hydrogen with the fluorine bioisostere does not exert significant steric demand at binding sites.A very similar strategy was used in the design of the cholesterol absorption inhibitor, ezetimibe from a lead compound.
J. Med. Chem., 2004, 47 (1), pp 1–9.
Reductive drug metabolism reactions, which tend to be facilitated by reductases, can occur with drugs containing carbonyl, azo, and nitro groups.Carbonyl groups can be reduced to alcohols whereas nitro and azo groups are reduced to amino derivatives. Following reduction, hydroxyl and amino functional groups can readily undergo further Phase II conjugation reactions. The oral contraceptive levonorgestrel, colloquially known as ‘the morning after pill’, is an example of a drug that can go through reductive Phase I biotransformations.
Other less encountered reductive pathways of biotransformations include N-oxide reduction to tertiary amines and the reduction of sulfoxide groups to thioethers. The bioprecursor prodrug, sulindac has a sulfoxide functional group that is converted to the active NSAID by enzymes in the body.
Hydrolytic reactions are catalysed by enzymes found in plasma, in certain tissues, and certain organs. Functional moieties can can readily undergo enzyme-mediated hydrolysis include esters and amides. Esterases (for ester bonds)and amidases (for amides) are examples of families of hydrolytic enzymes. The biotransformation of aspirin to salicylic acid is a well-known example of ester hydrolysis.
Phase I functionalisations don’t always give rise to pharmacologically inactive, nontoxic, or sufficiently hydrophilic metabolites. Phase II reactions often render metabolites more hydrophilic by attaching small, ionisable, and polar molecules to certain functional groups in the drug or the drug’s metabolites.The resulting metabolites are generally inactive and readily excretable.
Phase II reactions are mostly conjugation reactions. which are typically catalysed by transferaseenzymes. Other phase II reactions such as methylation and acetylation often serve to put an end to or diminish pharmacological activity.The different Phase II reactions will now be discussed.
Glucuronic Acid Conjugation
Glucuronidation is the most common Phase II reaction. D-Glucuronic acid is derived from D-Glucose. Carboxylic acids, alcohols, phenols, and hydroxylamine can undergo glucuronidation. Glucuronosyl transferases (UGTs) are the transferases involved with the reaction.Structures of some drugs and the site of glucuronidation are shown below: naproxen&desipramine.
Sulfate conjugation of xenobiotics is less common compared to glucuronidation. These reactions mainly occur with phenols and sometimes aromatic amines, N-hydroxy compounds, and alcohols. The β-adrenergic bronchodilator, salbutamol is known to undergo sulfate conjugation.
Glutathione (GSH) is a tripeptide that is involved in the detoxification of reactive electrophilic compounds or intermediates. Glutathione S-Transferases (GSH S-Transferase) are the enzymes that catalyse the conjugation of this molecule with drugs.In general, compounds that react with GSH do so through a nucleophilic attack on an electrophilic carbon with a good leaving group or through addition to electron-deficient double bonds.Reactive electrophiles are toxic due to their ability to form covalent bonds with important macromolecules such as cellular proteins and nucleic acids. Depletion of GSH is associated with the toxicity observed with paracetamol (acetaminophen) overdose.
Paracetamol can be converted to NAPQI (N-acetyl-p-benzoquinone imine) during Phase I reactions by CYP450 enzymes. NAPQI is a highly reactive compound. At safe doses of the drug, Phase II GSH conjugation reactions convert toxic NAPQI to a non-toxic metabolite. At unsafe doses of paracetamol, excess NAPQI is generated. GSH is eventually depleted and NAPQI begins reacting with nucleophilic groups in cellular macromolecules. This reaction is detrimental to the organism.
Drug Design & Drug Discovery
Knowledge of drug metabolism is of immense value to medicinal chemists. During drug design, molecules may be designed such that they don’t form toxic metabolites. This knowledge can also be used as a guide to assist researchers in making molecules have optimal pharmacokinetic properties. Studies of metabolism can be useful in drug discovery as well. For example, the known potassium channel-opening vasodilator, cromakalim was discovered through these studies. Compound I was discovered to have less activity in vitro than in vivo which suggests that this compound was converted to a more active compound in living systems. The more active metabolite, cromakalim was eventually discovered.
The study of drug metabolism and drug design are closely related. Having knowledge of both leads to the development of safe, clinically advantageousproducts.